doi: 10.1161/CIRCULATIONAHA.105.572396
(Circulation. 2005;112:3400-3407.)
© 2005 American Heart Association, Inc.
Heart Failure |
Critical Role for Monocyte Chemoattractant Protein-1 and Macrophage Inflammatory Protein-1
in Induction of Experimental Autoimmune Myocarditis and Effective Anti–Monocyte Chemoattractant Protein-1 Gene Therapy
From the Department of Internal Medicine III (Z.K., S.G., R.Ö., A.B., T.J.D., H.A.K.), University of Heidelberg, Germany; the Department of Internal Medizin II (J.T.), University of Ulm, Germany; the Graduate School of Medical Sciences (K.E.), Kyushu University, Fukuoka, Japan; and the Departments of Pathology and Molecular Microbiology and Immunology (N.R.R.) of The Johns Hopkins Medical Institutions, Baltimore, Md.
Correspondence to Ziya Kaya, Department of Internal Medicine III, University of Heidelberg, INF410, 69120 Heidelberg, Germany. E-mail ziya_kaya{at}med.uni-heidelberg.de
Received June 29, 2005; revision received August 12, 2005; accepted September 2, 2005.
Background— Autoimmune myocarditis is a principal cause of heart failure among young adults and is often a precursor of dilated cardiomyopathy. Monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1
(MIP-1) are potent chemotactic factors for mononuclear cells. The inflammatory infiltrate observed in myocardial lesions of myocarditis consists of >70% mononuclear cells. To determine their critical role in the pathogenesis of myocarditis, we inhibited mononuclear cell activation and migration to see if it would affect disease severity and disease prevalence in experimental autoimmune myocarditis (EAM).
Methods and Results— In this report, we demonstrated that blockade of MCP-1 or MIP-1 with monoclonal antibodies significantly reduced severity of myocarditis in BALB/c mice immunized with cardiac myosin. Similar results were obtained when CCR2–/– and CCR5–/– mice were used. In CCR2–/– mice, not only disease severity but also disease prevalence was reduced. To further inhibit mononuclear cell activation and migration, we transfected the mice before inducing EAM with a dominant-negative inhibitor of MCP-1 gene (7ND). This transfection significantly reduced the disease severity, decreased mRNA expression levels, especially of the chemokines RANTES, MIP-2, IP-10, MCP-1, T-cell activation gene 3, and eotaxin in the myocardium, and resulted in a reduction in cardiac myosin-induced interleukin-1 and interleukin-4 and in an increase in interferon-
and interleukin-10 cytokine production by splenocytes.
Conclusions— Overall, these findings suggest that the chemokines MCP-1 and MIP-1, acting through their receptors CCR2 and CCR5, are important in the induction of EAM and that inhibition of MCP-1 with 7ND gene transfection significantly reduced disease severity. This strategy may be a new feasible form of gene therapy against autoimmune myocarditis.
Key Words: myosin • myocarditis • inflammation • gene therapy
This article has been cited by other articles:
 |
|
 |
|
  C. N. Paiva, R. T. Figueiredo, K. Kroll-Palhares, A. A. Silva, J. C. Silverio, D. Gibaldi, A. d. S. Pyrrho, C. F. Benjamim, J. Lannes-Vieira, and M. T. Bozza CCL2/MCP-1 controls parasite burden, cell infiltration, and mononuclear activation during acute Trypanosoma cruzi infection J. Leukoc. Biol., November 1, 2009; 86(5): 1239 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Izhak, G. Wildbaum, Y. Zohar, R. Anunu, L. Klapper, A. Elkeles, J. Seagal, E. Yefenof, M. Ayalon-Soffer, and N. Karin A Novel Recombinant Fusion Protein Encoding a 20-Amino Acid Residue of the Third Extracellular (E3) Domain of CCR2 Neutralizes the Biological Activity of CCL2 J. Immunol., July 1, 2009; 183(1): 732 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shehadeh, S. Pollack, G. Wildbaum, Y. Zohar, I. Shafat, R. Makhoul, E. Daod, F. Hakim, R. Perlman, and N. Karin Selective Autoantibody Production against CCL3 Is Associated with Human Type 1 Diabetes Mellitus and Serves As a Novel Biomarker for Its Diagnosis J. Immunol., June 15, 2009; 182(12): 8104 - 8109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Kaya, S. Goser, S. J. Buss, F. Leuschner, R. Ottl, J. Li, M. Volkers, S. Zittrich, G. Pfitzer, N. R. Rose, et al. Identification of Cardiac Troponin I Sequence Motifs Leading to Heart Failure by Induction of Myocardial Inflammation and Fibrosis Circulation, November 11, 2008; 118(20): 2063 - 2072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Hsieh, M. Frink, Y.-C. Hsieh, W.-H. Kan, J.-T. Hsu, M. G. Schwacha, M. A. Choudhry, and I. H. Chaudry The Role of MIP-1{alpha} in the Development of Systemic Inflammatory Response and Organ Injury following Trauma Hemorrhage J. Immunol., August 15, 2008; 181(4): 2806 - 2812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Valaperti, R. R. Marty, G. Kania, D. Germano, N. Mauermann, S. Dirnhofer, B. Leimenstoll, P. Blyszczuk, C. Dong, C. Mueller, et al. CD11b+ Monocytes Abrogate Th17 CD4+ T Cell-Mediated Experimental Autoimmune Myocarditis J. Immunol., February 15, 2008; 180(4): 2686 - 2695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Stumpf, C Lehner, D Raaz, A Yilmaz, T Anger, W G Daniel, and C D Garlichs Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure Heart, January 1, 2008; 94(1): 65 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Reifenberg, H.-A. Lehr, M. Torzewski, G. Steige, E. Wiese, I. Kupper, C. Becker, S. Ott, P. Nusser, K.-I. Yamamura, et al. Interferon-{gamma} Induces Chronic Active Myocarditis and Cardiomyopathy in Transgenic Mice Am. J. Pathol., August 1, 2007; 171(2): 463 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goser, M. Andrassy, S. J. Buss, F. Leuschner, C. H. Volz, R. Ottl;, S. Zittrich;, N. Blaudeck, S. E. Hardt, G. Pfitzer, et al. Cardiac Troponin I but Not Cardiac Troponin T Induces Severe Autoimmune Inflammation in the Myocardium Circulation, October 17, 2006; 114(16): 1693 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bidzhekov, A. Zernecke, and C. Weber MCP-1 Induces a Novel Transcription Factor With Proapoptotic Activity Circ. Res., May 12, 2006; 98(9): 1107 - 1109. [Full Text] [PDF]
|
|